ArticleJournal of human hypertension2005
The controversial role of serum uric acid in essential hypertension: relationships with indices of target organ damage.
Article in Journal of human hypertension, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- Association of serum uric acid with mortality and cardiovascular outcomes in patients with hypertension: a meta-analysis.Journal of thrombosis and thrombolysis · 2021Pooled it
- Correlation between serum uric acid levels and target organ damage in apparently healthy subjects with newly diagnosed Grade I/Grade II essential hypertension: An observational cross-sectional study.Journal of family medicine and primary care · 2026Article
- The Prevalence, Distribution, and Extent of Subclinical Atherosclerosis and Its Relation With Serum Uric Acid in Hypertension Population.Frontiers in cardiovascular medicine · 2021Article
- Serum uric acid and left ventricular hypertrophy in hypertensive patients in Ado-Ekiti.The Pan African medical journal · 2020Article
- Uric Acid and Arterial Stiffness.Therapeutics and clinical risk management · 2020Review
- Serum Uric Acid and Left Ventricular Mass in Essential Hypertension.Frontiers in cardiovascular medicine · 2020Article
- Increased Serum Uric Acid Level Is a Risk Factor for Left Ventricular Hypertrophy but Not Independent of eGFR in Patients with Type 2 Diabetic Kidney Disease.Journal of diabetes research · 2017Article
- Gender-related differences in the association between serum uric acid and left ventricular mass index in patients with obstructive hypertrophic cardiomyopathy.Biology of sex differences · 2016Article
- Bilirubin Level is Associated with Left Ventricular Hypertrophy Independent of Blood Pressure in Previously Untreated Hypertensive Patients.Korean circulation journal · 2014Article
- Hyperuricemia and renal risk.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2014Review
- Serum uric acid and target organ damage in essential hypertension.Vascular health and risk management · 2014Article
- The diverse associations of uric acid with low-grade inflammation, adiponectin and arterial stiffness in never-treated hypertensives.Journal of human hypertension · 2011Article
- Gout, hyperuricemia, and the risk of cardiovascular disease: cause and effect?Current rheumatology reports · 2010Review
- Towards improving the clinical assessment and management of human hypertension: An overview from this Journal.Journal of human hypertension · 2006Review
- Serum uric acid as a risk factor for cardiovascular and renal disease: an old controversy revived.Journal of clinical hypertension (Greenwich, Conn.) · 2006Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The role of serum uric acid (SUA) in the context of adverse cardiovascular events in hypertensive subjects is controversial. Additionally, the relationship between SUA and indices of target organ damage is not well defined in this setting. Towards this end, we studied 842 consecutive nondiabetic patients with stage I-II essential hypertension (office blood pressure=148/95 mmHg, aged 53.4 years), referred to our outpatient hypertensive unit within a period of 4 years. According to the urinary albumin excretion (UAE), the study population was classified into those with microalbuminuria [MA(+), UAE=20-200 mg/24 h, n=222] and those without MA [MA (-), UAE< 20 mg/24 h, n=620]. Moreover, according to the presence of left ventricular hypertrophy (LVH) the participants were subdivided into two additional groups: [LVH (+), n=305 and LVH (-), n=537]. SUA levels were higher by 0.4 mg/dl, (P=0.04) in group MA (+) compared with the group MA (-), while no difference was observed between groups LVH (+) and LVH (-) (P=NS). In the entire population, SUA was correlated with body mass index (BMI) (r=0.17, P<0.001), waist/hip ratio (r=0.3, P<0.001), office systolic blood pressure (SBP) (r=0.14, P<0.05), triglycerides levels (r=0.25, P<0.001), UAE (r=0.35, P<0.001) and HDL (r=-0.26, P<0.001). Multiple regression analysis demonstrated that SUA was significantly related with BMI, office SBP and UAE (P<0.05). In conclusion, increased SUA levels are associated with MA but not with LVH in essential hypertensive subjects. Whether these inter-relationships may elucidate the clinical positioning of augmented SUA in this setting remains to be clarified in future studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.